China News Service, July 29 (Chen Jing, Sun Guogen, Chen Lin) The development of small molecule target drugs for newly discovered metabolic targets is one of the important frontiers of anti-tumor drug innovation.
The reporter learned on the 29th that in recent years, the research group of Professor Zhou Lu from the School of Pharmacy of Fudan University has focused on this field and carried out a large number of cutting-edge innovative research.
The reporter learned on the 29th that Fudan University signed a contract with Shanghai Ailisi Medical Technology Co., Ltd. to jointly develop the first anti-tumor target small molecule inhibitors successfully developed by Professor Zhou Lu's team.
This is expected to introduce small-molecule targeted drugs that can be used for clinical treatment as soon as possible to benefit cancer patients.
Fudan University attaches great importance to the transformation of scientific and technological achievements in the field of biomedicine. This year alone, the contract amount for the transformation of scientific and technological achievements has exceeded 900 million yuan.
Photo courtesy of School of Pharmacy, Fudan University
According to reports, PGAM1 is a potential new target for anti-tumor metabolism.
Aiming at this new target, Professor Zhou Lu's team developed a series of related inhibitors represented by KH3 with independent intellectual property rights in the early stage.
Among them, KH3 has been proved to have a significant inhibitory effect on pancreatic ductal adenocarcinoma in a variety of preclinical models of pancreatic cancer, opening a new chapter of "targeted inhibition of tumor metabolic pathways" for the precise treatment of pancreatic cancer.
It is understood that these results have been published in the first-class international journals "Proceedings of the National Academy of Sciences" and "Cell Metabolism", providing new directions and leading small molecule compounds for the development of a new class of original anti-tumor drugs with a new mechanism of action.
It is reported that in recent years, Fudan University has attached great importance to the transformation of scientific and technological achievements in the field of biomedicine. Only this year, the contract amount for the transformation of scientific and technological achievements has exceeded 900 million yuan.
Shanghai Ailisi Pharmaceutical Technology Co., Ltd. is an innovative pharmaceutical company focusing on the field of tumor treatment.
(Finish)